 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...202203204205206207208209210211212...235236» |
- Enrollment open, Metastases: Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla (clinicaltrials.gov) - Jan 20, 2016
P2, N=37, Recruiting, Sponsor: Essentia Health
Not yet recruiting --> Recruiting
- | tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial completion, Trial primary completion date, Combination therapy, Metastases: Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach (clinicaltrials.gov) - Jan 19, 2016
P1/2, N=47, Completed, Sponsor: SCRI Development Innovations, LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jul 2015
- ||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
New P1 trial, Combination therapy, Metastases: Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (clinicaltrials.gov) - Jan 19, 2016
P1, N=80, Not yet recruiting, Sponsor: AstraZeneca
- ||| Jakafi oral (ruxolitinib) / Novartis, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 19, 2016
P2, N=92, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jul 2015 Recruiting --> Active, not recruiting
- || vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 17, 2016
P2, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2017 --> Dec 2017
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Genistein in Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 17, 2016
P1/2, N=24, Recruiting, Sponsor: Randall F. Holcombe
Trial primary completion date: Sep 2017 --> Dec 2017 Trial primary completion date: May 2016 --> May 2018
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Surgery: Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis (clinicaltrials.gov) - Jan 17, 2016
P2, N=39, Recruiting, Sponsor: Korea Cancer Center Hospital
Trial primary completion date: May 2016 --> May 2018 Trial primary completion date: Aug 2014 --> Aug 2017
- Trial primary completion date: A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 17, 2016
P2, N=39, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Aug 2014 --> Aug 2017 Trial primary completion date: Aug 2016 --> Aug 2017
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies (clinicaltrials.gov) - Jan 17, 2016
P1, N=45, Recruiting, Sponsor: University of Chicago
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Mar 2016 --> Mar 2017
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Study of Vitamin D in Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 17, 2016
P2, N=120, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Mar 2016 --> Mar 2017 Trial primary completion date: Apr 2016 --> Jul 2016
- || Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 17, 2016
P1, N=83, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2016 --> Jul 2016 Trial primary completion date: Apr 2016 --> Apr 2018
- || pegilodecakin (LY3500518) / Eli Lilly
Enrollment change, Trial primary completion date: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jan 15, 2016
P1, N=300, Recruiting, Sponsor: ARMO BioSciences
Trial primary completion date: Apr 2016 --> Apr 2018 N=135 --> 300 | Trial primary completion date: Dec 2015 --> Dec 2016
- Enrollment change, Surgery: Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") (clinicaltrials.gov) - Jan 15, 2016
P2, N=120, Recruiting, Sponsor: Medical College of Wisconsin
N=135 --> 300 | Trial primary completion date: Dec 2015 --> Dec 2016 N=100 --> 120
- |||| Avastin (bevacizumab) / Roche
Biomarker, Trial completion, Trial primary completion date, Metastases: MAVERICC: Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jan 15, 2016
P2, N=376, Completed, Sponsor: Genentech, Inc.
N=100 --> 120 Active, not recruiting --> Completed | Trial primary completion date: Oct 2014 --> May 2015
- || prexasertib (ACR-368) / Acrivon Therap
Enrollment change, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Jan 11, 2016
P1, N=185, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | Trial primary completion date: Oct 2014 --> May 2015 N=115 --> 185
- Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open, Metastases: MINOAS: Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment (clinicaltrials.gov) - Jan 11, 2016
P2, N=89, Recruiting, Sponsor: Hellenic Oncology Research Group
N=115 --> 185 Not yet recruiting --> Recruiting
- varlitinib (ASLAN001) / ASLAN Pharma
New P1 trial, Combination therapy: Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine (clinicaltrials.gov) - Jan 7, 2016
P1, N=24, Recruiting, Sponsor: Aslan Pharmaceuticals
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma
New P1 trial, Combination therapy, Metastases: Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors (clinicaltrials.gov) - Jan 7, 2016
P1, N=36, Recruiting, Sponsor: Cerulean Pharma Inc.
- Trial primary completion date, Surgery, Metastases: Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer (clinicaltrials.gov) - Jan 4, 2016
P2, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Dec 2016
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Trial initiation date, Surgery: Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining (clinicaltrials.gov) - Jan 4, 2016
P=N/A, N=40, Recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Dec 2015 --> Dec 2016 Initiation date: Nov 2015 --> Jun 2015
- ||||||| onartuzumab (RG3638) / Roche
Trial completion, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - Jan 4, 2016
P3, N=564, Completed, Sponsor: Hoffmann-La Roche
Initiation date: Nov 2015 --> Jun 2015 Active, not recruiting --> Completed
- || oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg.
Trial primary completion date: Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ) (clinicaltrials.gov) - Dec 31, 2015
P2, N=58, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Jan 2017 --> Jan 2018
- Avastin (bevacizumab) / Roche, napabucasin (BBI608) / Sumitomo Pharma
New P1 trial, Metastases: A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 30, 2015
P1, N=6, Recruiting, Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Enrollment open, Trial initiation date, Surgery: Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining (clinicaltrials.gov) - Dec 30, 2015
P=N/A, N=40, Recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Jan 2017 --> Jan 2018 Not yet recruiting --> Recruiting | Initiation date: Jun 2015 --> Nov 2015
- |||||| Bavencio (avelumab) / EMD Serono
Enrollment open, Metastases: Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) (clinicaltrials.gov) - Dec 29, 2015
P3, N=629, Recruiting, Sponsor: EMD Serono
Not yet recruiting --> Recruiting | Initiation date: Jun 2015 --> Nov 2015 Not yet recruiting --> Recruiting
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Enrollment open, PD(L)-1 Biomarker, Metastases: Study of Pembrolizumab With REOLYSIN (clinicaltrials.gov) - Dec 29, 2015
P1, N=9, Recruiting, Sponsor: Oncolytics Biotech
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier
Clinical: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 29, 2015
P3, N=63, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New trial: NORMAL-R: Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum (clinicaltrials.gov) - Dec 29, 2015
P0, N=20, Not yet recruiting, Sponsor: Washington University School of Medicine
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P1 trial, Metastases: DOUBLIRI: A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer (clinicaltrials.gov) - Dec 29, 2015
P1, N=36, Recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Phase I Trial of Combination of FOLFIRI and SOM 230 (clinicaltrials.gov) - Dec 25, 2015
P1, N=16, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2015
- Trial completion: Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT (clinicaltrials.gov) - Dec 25, 2015
P2, N=25, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2015 Active, not recruiting --> Completed
- Trial primary completion date, Metastases: Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer (clinicaltrials.gov) - Dec 23, 2015
P2, N=32, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Trial primary completion date: Jul 2015 --> Jul 2016
- methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Nov 2015 --> Nov 2016
- ||||| HyperAcute Pancreas (algenpantucel-L) / Lumos Pharma
Enrollment closed, Metastases: Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov) - Dec 23, 2015
P3, N=302, Active, not recruiting, Sponsor: NewLink Genetics Corporation
Trial primary completion date: Nov 2015 --> Nov 2016 Recruiting --> Active, not recruiting
- Enrollment change, Trial termination, Trial primary completion date: Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Dec 21, 2015
P2, N=1, Terminated, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting N=50 --> 1 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2015; Slow accrual
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Trial primary completion date, Metastases: METHEP-2: Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases (clinicaltrials.gov) - Dec 18, 2015
P2, N=256, Active, not recruiting, Sponsor: UNICANCER
N=50 --> 1 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2015; Slow accrual Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Nov 2016
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Trial primary completion date, Metastases: PRODIGE 18: Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab (clinicaltrials.gov) - Dec 18, 2015
P2, N=132, Active, not recruiting, Sponsor: UNICANCER
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Nov 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Oct 2015
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Surgery: Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer (clinicaltrials.gov) - Dec 16, 2015
P2, N=46, Recruiting, Sponsor: Yale University
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Oct 2015 Trial primary completion date: Dec 2016 --> Dec 2018
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) - Dec 15, 2015
P1/2, N=25, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial primary completion date: Dec 2016 --> Dec 2018 Trial primary completion date: Sep 2013 --> Sep 2016
- ||| andecaliximab (GS-5745) / Gilead
Enrollment open, Combination therapy, Monotherapy, Metastases: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Dec 15, 2015
P1, N=313, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Sep 2013 --> Sep 2016 Active, not recruiting --> Recruiting
- leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: VELVET: OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 12, 2015
P2, N=49, Active, not recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Mar 2016
- leucovorin calcium / Generic mfg.
Enrollment change: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Dec 12, 2015
P2, N=99, Terminated, Sponsor: University of Arkansas
Trial primary completion date: Dec 2015 --> Mar 2016 N=160 --> 99
- | Enrollment closed, Trial primary completion date: IDEA: Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer (clinicaltrials.gov) - Dec 12, 2015
P3, N=2000, Active, not recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
N=160 --> 99 Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2016
- New P2 trial, Metastases: Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla (clinicaltrials.gov) - Dec 10, 2015
P2, N=37, Not yet recruiting, Sponsor: Essentia Health
- || Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: Everest 2: Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (clinicaltrials.gov) - Dec 10, 2015
P2, N=375, Active, not recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2016 Trial primary completion date: Mar 2015 --> Mar 2016
- ||| Vectibix (panitumumab) / Amgen
New trial, HEOR: SILQ: ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=300, Recruiting, Sponsor: Amgen
- |||||||||| Bavencio (avelumab) / EMD Serono
New P3 trial, Metastases: Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) (clinicaltrials.gov) - Dec 10, 2015
P3, N=629, Not yet recruiting, Sponsor: EMD Serono
- Truseltiq (infigratinib) / BridgeBio, Pfizer, Xediton Pharma
Trial initiation date, Metastases: Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 9, 2015
P1/2, N=78, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Mar 2015 --> Mar 2016 Initiation date: Oct 2015 --> Jan 2016
- | Zaltrap (ziv-aflibercept IV) / Sanofi
New P2 trial, Metastases: MINOAS: Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment (clinicaltrials.gov) - Dec 9, 2015
P2, N=89, Not yet recruiting, Sponsor: Hellenic Oncology Research Group
- || SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial primary completion date: SIRFLOX: FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer (clinicaltrials.gov) - Dec 7, 2015
P=N/A, N=518, Active, not recruiting, Sponsor: Sirtex Medical
Initiation date: Oct 2015 --> Jan 2016 Trial primary completion date: Sep 2014 --> Jan 2017